
10,000 NZers may have lost vision due to toxoplasmosis
Ten thousand New Zealanders may have lost vision - sometimes permanently - due to toxoplasmosis, an infection triggered by a parasite spread by cats.
Otago University researchers estimate 40,000 people are affected by ocular toxoplasmosis - one in four seriously - but their efforts to develop new treatments are being hampered by a lack of funding.
Danielle Wilson was at work when her vision went blurry.
"I just had like a sudden onset of really sore, red eye and my vision changed, and I couldn't stand bright lights."
Luckily, she works as a nurse in the eye department at Otago University.
"I made myself an appointment to see an optometrist after work, but my colleagues being observant eye staff, all noticed my red eye so they scooped me up and took me and checked my eyes out."
Wilson, who is in her early 30s, was shocked to learn she had toxoplasmosis in her eye.
Doctors told her the parasite - commonly spread by cats - could have lain dormant in her body for years.
Treatment was intense - for the first week, she needed to take eyedrops every hour, and she was on antibiotics and courses of steroids for 18 months.
A couple of years on, she is "always nervous" it could flare up again, and is vigilant for any changes in her eye.
"Unfortunately the scar on my eye is really close to my central vision, so if the scar gets worse, I could lose that vision permanently."
NZ has high rates of infection
Toxoplasma is the leading cause of infectious eye diseases globally and a major contributor to vision loss in New Zealand.
Dr Francesc March de Ribot, Ophthalmology Consultant, Otago University Photo: Supplied
Otago University ophthalmologist Dr Francesc March de Ribot regularly sees patients with toxoplasmosis, including very young people.
One of them, a medical student, has lost central vision in one eye, which has killed his dream of becoming a surgeon.
"When there is inflammation in the retina, the vision becomes blurry, and sometimes we can see when the inflammation goes away, it leaves a scar, and the vision is never going to recover."
World-wide, up to one in three people are infected - but rates could be even higher in New Zealand: 43 percent according to one study in Waikato.
The parasite, Toxoplasma gondii, reproduces in cat guts and is spread through eggs in their faeces.
Cat poo in soil and freshwater can infect birds and mammals, including humans, with toxoplasmosis for up to two years, while the eggs survive in sea water for six months.
For unborn babies and those with weakened immune systems, toxoplasmosis can cause blindness, brain damage and even death - but for most people, it is no worse than a cold.
However, the parasite can live dormant within cysts inside the body, and make people sick when it "reactivates".
De Ribot said it was estimated to seriously affect the sight of about 10,000 New Zealanders, with 1000 recurrences a year.
"It's likely that maybe we have more incidences than other countries, and as well that some people have more difficulty in accessing eye care, so they are not detected or treated on time. So it's definitely a problem."
Research stymied by lack of funding
Otago University professor of parasitology Bruce Russell said current available treatments were not very effective.
"They don't work well against the dormant stage of the parasite. When people are found to have it, they need repeated and long-term treatments, and the current treatment doesn't stop the inflammation, which is the thing that actually destroys part of the eye. It causes retinal destruction."
The good news is Professor Russell has identified some promising compounds for new treatments - but he cannot get funding to develop them in New Zealand.
HIs latest application for a research grant - made with Dr March de Ribot and other top researchers - has just been rejected by the Marsden Fund.
They were asking for $900,000 over three years.
"We had a library of such drugs, that had already been part of a $420 million Novartis [Swiss-based multinational pharmaceutical company] target discovery programme that I was involved in, in Singapore. I try to sell this to people here, but I don't know, it doesn't seem to get through."
The Otago lab, which was testing drugs against both toxo and cryptosporidium, closed in 2023, due to lack of funding.
Most of Professor Russell's work has been farmed out overseas, with Singapore picking up the drug discovery work.
He said the developed world had largely forgotten about parasites.
"But there are a lot of hidden ones, like toxo, which we don't understand. And unfortunately I don't think we really want to try to understand, because if we knew their full impact, it would cause a lot of upset.
"For instance, we think there are probably some big impacts on mental health."
It could also explain why New Zealanders love cats and have one of the highest cat ownership rates in the world (40 percent of households), he (half) joked.
"The parasite rewires the brain of the mouse to go and find cats, so the cat can eat it, and complete the life cycle of the parasite."
Although toxoplasmosis is not a notifiable disease in New Zealand, 142 cases were reported between 2007-2016, including 15 cases of congenital toxoplasmosis (in babies infected in the womb).
It was not just a problem for people, Russell said.
"Toxoplasmosis is a killer of some of our precious native wildlife, including birds like kiwi and kākā, and our unique Hector's and Māui dolphins. It also causes big problems for sheep farmers, leading to the loss of lambs."
Doctors advise people who are pregnant or have a weakened immune system should not eat raw, undercooked or cured meats or products made from unpasteurised milk, wear gloves when emptying cat litter trays, cover children's sandpits, wear gloves to garden and wash their hands before preparing food and eating.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scoop
4 hours ago
- Scoop
New Project Tackles Breast Cancer Inequity
A major new project focused on Māori women with breast cancer is launching, with a $5 million grant from the Health Research Council. University of Auckland Associate Professor George Laking from Te Aka Mātauranga Matepukupuku, Centre for Cancer Research is leading the Whiria te Aka Matua project, with Dr Nina Scott from Te Whatu Ora, Health New Zealand. The five-year project will offer a new model of care designed to overcome inequities faced by Māori women with breast cancer, says Laking. Wāhine Māori have a 46 percent higher incidence of breast cancer than European New Zealanders, he says. When breast cancer is picked up by screening, Māori women have the same chance of survival as other New Zealanders. However, about 45 percent of all wāhine Māori who have breast cancer are diagnosed outside of screening programmes, after they notice symptoms, such as a lump. Māori women with symptomatic breast cancer have a 37 percent lower rate of survival than European New Zealanders, he says. 'The reasons for this are many, but one of the things we urgently need to improve is the design of the health system. 'We hope the model of care we are developing will turn the inequity around, so there's no longer a survival disadvantage for Māori women with symptomatic breast cancer,' says Laking. The research team includes experts from Waipapa Taumata Rau, University of Otago, and Waikato and Auckland hospitals. They aim to enrol 160 Māori women with suspected breast cancer into their study. The women who are diagnosed with breast cancer will receive wrap-around care for themselves and their whānau. Three interventions will be offered, starting with the whiri model of care. This involves a health navigator ensuring the whānau know what is happening, what health services are needed and how to get to appointments. The health navigator will assess the health of the whole family. 'We want to implement a family model of care, in contrast to prevalent models that are centred on individual patients. 'Major health issues have flow-on effects through families. Sometimes one person is diagnosed with cancer and a family member worries themselves sick. 'We want to make sure the health of all people in the family is on track, at a time when they need it,' says Laking. The next intervention will be Whānau Hauora Portfolios. These will provide a core plan of care, which can be easily updated and communicated with different teams. They will also be a place where whānau can record what happens on the cancer journey. The third intervention will be prehabilitation, a holistic programme designed to prepare women for the stress of treatments, such as surgery, radiation and chemotherapy. Prehabilitation - occuring between diagnosis and when treatment begins - could include support with exercise, nutrition, psychological and social needs, and rongoā Māori. 'It will help make sure women are as well as possible at the beginning of their cancer treatment. 'In European populations with cancer, prehabilitation has been shown to shorten the average length of hospital stay and to reduce post-surgical complications,' says Laking. Two evaluations will be offered – the first, assessing signs of inflammation in the women's blood samples, to see how these are affected by prehabiltation and cancer treatments. A holistic evaluation of the value of the entire programme will also be presented. The kete of resources will be co-designed with wāhine Māori with breast cancer, through interviews and focus groups. Several wānanga will be held to collaborate with the wider health community on the programme. Laking says what works for Māori women will have benefits for many patient communities. 'We're focusing our research on Māori women, because that's the area of greatest immediate need, but the model of care we're developing will be useful for all New Zealand women with breast cancer. 'This model could be relevant for a wide range of conditions, not just in Aotearoa, but globally,' says Laking.

RNZ News
6 hours ago
- RNZ News
Ministry of Health forced to release documents showing alcohol lobby influence
The spirits industry says it supports targeted programmes but believes the draft Fetal Alcohol Spectrum Disorder strategy is too broad. File photo Photo: By Angie Garrett from Ridgely, USA [CC BY 2.0 ( via Wikimedia Commons Alcohol lobbyists pushed health officials not to raise taxes, curb supply or cut industry sponsorship of sport - despite those measures being endorsed by the World Health Organisation as among the most effective ways to reduce alcohol harm. The tactics are laid bare in documents the Ministry of Health tried to keep secret, only releasing them after RNZ appealed to the Ombudsman. They also show industry efforts to shape a government strategy to combat Fetal Alcohol Spectrum Disorder (FASD). Officials handed the draft FASD plan to alcohol companies for feedback - while keeping it from the public. Spirits New Zealand dismissed estimates that up to 3000 babies are born with the disorder each year as "not credible" and attacked a taxpayer-funded ad campaign from 2019, even though it won five awards. Health Coalition Aotearoa said the industry should have no role in shaping alcohol policy. But the ministry's deputy director general Andrew Old defended its engagement, insisting companies had no special access. "They certainly haven't had any particular special treatment or back door into the ministry. It's been a deliberate, structured approach. They've had quarterly meetings with the team," Old said. "I can absolutely and categorically say that there is no veto power. So if the industry says 'we don't want to see this', that has no bearing on the outcome. It is a view that is considered alongside a range of other views." Old accepted the alcohol industry was motivated by profit. "I also would hope that, in doing that, they don't want to be doing harm," he said. "There's clearly a conflict. But, to my mind, it's not an irreconcilable conflict that would mean that we should just never talk to them." Read more: Alcohol lobbyists were also given a draft investment strategy on how to spend the Alcohol Levy, a ring-fenced fund of $16.6 million for alcohol harm reduction measures. The documents include an email from Spirits NZ to the MOH, saying there was intense interest in the Alcohol Levy, which is funded from a small tax on sales - equivalent to less than one cent on a standard can of beer. "My members with global links are seeking advice from their HQ's from London to Louisville, Kentucky - yes, this is how important this matter is to them," the lobbyist says, in a November 2024 email to the MOH. The documents show industry concern the Alcohol Levy would be spent on programmes based on the WHO's SAFER strategy, which says that, globally, a person dies every ten seconds due to alcohol related causes. "The WHO SAFER strategies include measures like restricting availability and raising excise taxes," a submission from the Brewers Association says. "These broad based initiatives are generally seen as reducing consumption overall and not targeting harmful consumption." The Brewers Association said there was an "overemphasis on restrictions" in the WHO guidelines. "Metrics tied to SAFER principles could incentivise programmes that focus excessively on punitive measures, such as limiting availability and marketing, rather than collaborative, education-based harm reduction approaches." The Brewers Association also warned against using the Alcohol Levy to fund "controversial" programmes it believes won't reduce harmful consumption. "Examples raised in our meeting included research with little application actions in the outcomes, funding of legal support for opposition of licences and replacing sponsorship arrangements in sport organisations with funds from the levy." The documents, which the MOH tried to withhold using a section of the OIA designed to protect advice between Ministers and officials until overruled by the Ombudsman, also include industry critique of the FASD strategy. Spirits New Zealand, which represents the likes of Asahi, Bacardi, Diageo, Lion, Moet-Hennessy and Pernod Ricard, warned against launching action on FASD without knowing what the prevalence was. It took issue with estimates, based on international studies and expert opinion, that 3-5 percent of babies - 1800 to 3000 every year - are born with FASD. "This is simply not credible and is similar to the situation that existed when the last plan was developed in 2016," the lobbyists say. "We cannot see how any FASD-prevention plan can be started without good data as a baseline. We would ask that the Public Health Agency give assurances that work on measurement frameworks occurs prior to other plan elements being launched." Leigh Henderson, chair of the advocacy group FASD-CAN, was concerned the alcohol industry doubted the prevalence of FASD. "Are they saying, 'Okay, it's all right for 500 babies to be born, but not 1800," she asked. "We know it's not 100 percent preventable, but to try and downplay it in that way is just callous and not recognising the level of the problem." In a statement chief executive Robert Brewer said Spirits NZ "categorically denies" downplaying the extent of FASD. "The government can't fix a problem if it doesn't know its true extent, level of occurrence, who is affected and why and to do this you need good data. This is basic public policy." Henderson said the motivation of the industry was clear, given its opposition during the 20 year battle to get mandatory pregnancy warning labels on alcohol. The spirits industry says it supports targeted programmes but believes the draft FASD strategy is too broad. It raised the ad campaign 'Pre-Testie Bestie' as an example, saying its "ultimate audience seemed to be any woman of child-bearing age who may or may not be having sex and who may or may not be pregnant". It said that was "an impossible audience to communicate with" as the campaign, funded by the Health Promotion Agency (HPA), was trying to be both targeted and national. But the HPA (now part of Health New Zealand) said in its 2019 Annual Report that 38 percent of women aged 18 to 30 saw the campaign and 70 percent of them got the key message: "Don't drink if you are or might be pregnant". The Pre-Testie Bestie ad campaign won five Axis Awards. The spirits industry also took issue with the draft FASD strategy saying New Zealand is a country where "alcohol is highly accessible, use is normalised," and there are high rates of hazardous drinking. Brewer said hazardous drinking had declined over the last four years in New Zealand to just 16 percent of adults.


Otago Daily Times
7 hours ago
- Otago Daily Times
Vaccines in a tablet among projects to receive research council funding
The Health Research Council of New Zealand provides millions of dollars each year, to improve the health and wellbeing of New Zealanders, by identifying and supporting high-quality, high-value research that has far-reaching impacts. John Lewis takes a look at the 18 research projects at the University of Otago, which received $15.3 million in the latest round of grants. A fear of needles has long been one of the bones of contention when it comes to getting vaccinated in New Zealand. But now University of Otago researchers hope to remove that obstacle by creating vaccines in the form of a tablet. Project leader and School of Pharmacy researcher Professor Sarah Hook said vaccines were only beneficial if everyone was willing to be vaccinated. "This is currently not the situation in Aotearoa New Zealand. "We urgently need to investigate new approaches to improve vaccine uptake and develop culturally appropriate messaging and initiatives to promote equity in vaccine access." The multi-disciplinary research team received a $1.2 million Health Research Council of New Zealand grant yesterday to create a simple, safe and effective self-administered oral vaccine in a capsule form. She said vaccination was a key public healthcare intervention which prevented the spread of infectious diseases, and more recently, it was being used to treat chronic conditions such as cancer. So initially, their research focus would be on creating an oral influenza vaccine, and a novel vaccine treatment for colon cancer. For vaccines to provide health benefits, people must have the confidence and willingness to be vaccinated, and the ability to access vaccine delivery services, she said. Alongside the lab-based research, the group aimed to develop resources and initiatives for Māori and Pacific communities to support future vaccination programmes. "While we believe moving away from injections will be a major benefit to improve vaccine uptake, using a kaupapa Māori framework, we want to find out what other barriers exist that prevent people from being vaccinated. "In particular we would like to reduce inequities that exist around vaccine uptake by Māori and Pacific people. "In Aotearoa New Zealand, it is imperative we increase vaccination rates, especially in groups with lower vaccine coverage. "Our research aims to minimise access and engagement immunisation barriers and enhance vaccination acceptance." Prof Hook was delighted to receive the funding and said the team was keen to start work on "this exciting research". The project is one of 18 Health Research Council grants awarded to University of Otago researchers, worth more than $15.3m. The council also awarded a $1.2m grant for Otago researchers to advance size-inclusive healthcare, by studying the acceptability and utility of cervical screening self-tests for "big-bodied" people. University of Otago (Wellington) primary healthcare and general practice researcher Associate Prof Lesley Gray said New Zealand's cervical screening programme now offered a universal self-testing option, which was expected to reduce inequities in participation and cancer outcomes. However, big-bodied people had historically been overlooked in research and under-served in screening, which increased their risk of undetected cervical cancer. She said cervical cancer was now preventable through vaccination, screening and timely treatment, and it was vital that the programme worked for people of all body sizes. "There are high levels of stigma and bias in healthcare associated with body size and fatness that mean people delay seeking help. "That impacts the quality of care people receive. "A range of factors determine how accessible services are from the built environment in which we deliver care, to the equipment and language we use in practice. "For example, the supplied swab is a standard length. We are interested to know how practical this is for big-bodied people wanting to self-test," she said. Assoc Prof Gray said the research aimed to understand how well the new screening pathway, including self-testing, met their needs. "Our pragmatic qualitative approach involves partnering with health and community providers to recruit big-bodied people to share their cervical screening experiences. "Findings will guide the development of practical approaches and recommendations for implementing size-inclusive cervical screening with broader relevance across all health services." Investing in the delivery of size-inclusive screening would help improve coverage and achieve downstream reductions in cancer incidence and mortality, she said. Meat processing is New Zealand's largest manufacturing sector, worth $12.2 billion to the economy and employing 28,000 people. But it is a hazardous work environment and has multiple health risks. University of Otago Va'a o Tautai Centre for Pacific Health postdoctoral fellow Dr Jane Taafaki has been given a Health Research Council grant of nearly $400,000 to investigate the workplace hazards that thousands of meatworkers face each day. "Pacific peoples are overrepresented in this industry and experience high rates of injury and work-related harm — a trend which is a growing concern in rural towns," she said. The first-of-its-kind study would take a Pacific approach to investigating the connection between the risk exposures in these kinds of manual labour industries and workers' health. Taking place in meat plants in Oamaru, Balclutha and Pareora, and using Pasifika fa'afaletui and talanoa methodologies, the study would examine the type and extent of workplace injury and illness, and how they relate to wider concepts of wellbeing, perception of workplace safety, risk exposures, and absenteeism. "We really want the outcomes of the project to be useful and informative to both the industry, as well as agencies like Te Whatu Ora Health New Zealand, WorkSafe and ACC, so that there are positive outcomes for the workers and industry alike." She said the research aimed to develop an instrument suitable for determining the nature and magnitude of musculoskeletal and associated health impacts for Pasifika people working in rural meat processing. It would also support the development of health services to respond to the health needs of rural Pacific meatworkers and their families more effectively. A drug used to treat anaemia (iron deficiency) also has the ability to cross into the brain. So University of Otago (Christchurch) medical laboratory science researcher Associate Prof Tania Slatter and pathology and biomedical science Professor Gabi Dachs are proposing the drug could also be used to treat some brain metastasis, by exploiting unique properties of these metastases. Two-thirds of cancer deaths occur when cancers spread around the body, and when cancer spreads to the brain (brain metastases), patients have "a dismal prognosis", because the metastases are challenging to treat. Assoc Prof Slatter said new treatment strategies were urgently needed in New Zealand. The duo received $1,196,992 from the Health Research Council to investigate if brain metastases were vulnerable to the anaemia drug, she said. "In the clinic and the laboratory, we will test if brain metastases have an iron accumulation signature that leads to greater drug uptake, and if this is sufficient to target metastases by triggering cancer cell death by iron overload." She said the anaemia drug was relatively low-cost with a good safety record, and might provide a new treatment opportunity and improved prognosis for those with otherwise limited treatment options. Colorectal cancer is one of the leading causes of death in New Zealand — especially in Otago and Southland where there are particularly high levels. While chemotherapy is a key treatment, it often causes unpleasant side effects which can reduce a person's ability to tolerate the treatment, and ultimately it makes it less effective. University of Otago School of Physical Education, Sport and Exercise Science researcher Dr Brendon Roxburgh has received a council Emerging Researcher Grant of $400,000 to evaluate the feasibility of exercise during chemotherapy. He believed exercise during chemotherapy might reduce side effects and improve treatment outcomes. "This research will begin by talking with people who have received or are receiving chemotherapy for colorectal cancer, to understand what helps or prevents them from being active during treatment. "We will use this information to develop a patient resource that supports safe physical activity during chemotherapy. "We will then test whether a supervised exercise programme during treatment is safe, manageable, and acceptable for people with colorectal cancer." Dr Roxburgh said the research could lead to better support for patients during treatment, improve their health outcomes, and provide a cost-effective way to improve cancer care across New Zealand. Other grants • Other research grants awarded to University of Otago researchers by the Health Research Council.— • Department of medicine researcher Dr Sarah Appleby has received a $150,000 Explorer Grant to create a new blood test to predict cardiovascular events. • Department of pathology researcher Dr Silke Neumann has received a $150,000 Explorer Grant to enhance chemotherapy sensitivity in patients with diffuse gastric cancer. • Department of oral sciences researcher Dr Zeina Al Naasan has received a $150,000 Explorer Grant to create an AI-assisted, easy-to-use smartphone-based app that can alleviate barriers to accessing oral healthcare advice, especially in communities with the highest needs. • Pathology and biomedical science researcher Prof Madhav Bhatia has received a $150,000 Explorer Grant to find pharmaceuticals that will enhance the body's lymphatic drainage system and help drain away pancreatic inflammation. • Department of surgery and critical care researcher Prof Tim Eglinton and department of pathology and biomedical science researcher Dr Arthur Morely-Bunker received a council grant of $699,734 to improve gastrointestinal cancer outcomes with AI-enhanced digital pathology. • Department of surgery and critical care researcher Dr Oliver Lyons and department of preventive and social medicine researcher Prof Sue Crengle received $1,439,803 to tackle gender inequity and provide better guidelines for doctors treating women with aneurisms. • Department of medicine researcher Dr Anna Pilbrow and department of pathology and biomedical science researcher Dr George Wiggins received $1,199,926 to study whether copy-number variation is a source of missing heritability for heart failure. • Department of biochemistry researcher Prof Parry Guilford and School of Pharmacy researcher Dr Jessica Fairhall received $1,199,177 from the council to investigate direct-to-stomach delivery of drugs for the chemoprevention of inherited stomach cancer. • Department of anatomy researchers Dr Michael Pankhurst and Prof Greg Anderson received $1,199,974 to study whether excessive ovarian hormones cause ovulation failure in polycystic ovary syndrome. • Department of physiology researcher Prof Peter Jones received $1,197,729 to study the treatment of Alzheimer's disease via inhibition of ryanodine receptors. • Department of biochemistry researcher Prof Sally McCormick received $1,170,000 to uncover the connection between serotonin and a form of blood cholesterol metabolism (Lp(a)). • Department of population health researchers Dr Rose Crossin and Prof Joseph Boden received $1,199,970 to define and measure drug (nicotine, alcohol, illicit drugs) harm for youth in New Zealand • Department of surgical sciences researcher Prof Greg Jones received $1,107,917 to improve how we predict someone's risk of cardiovascular disease, by testing a new blood test that more accurately measures a person's lifetime exposure to smoking.